Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

NCT00347802

Glaucoma

COMPLETED PHASE4

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

NCT00440011

Glaucoma Ocular Hypertension

COMPLETED PHASE4

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01068964

Open-angle Glaucoma Ocular Hypertension

COMPLETED NA

Safety and Efficacy of Changing to DuoTrav From Prior Therapy

NCT01230736

Glaucoma

COMPLETED PHASE4

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

NCT00763061

Glaucoma

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* · Male or female \> 18 years of age

* Diagnosis of primary open-angle glaucoma or ocular hypertension
* Untreated IOP \> 18 mm Hg in each eye at the baseline evaluation
* Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria

* · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication

* Uncontrolled systemic disease
* Active ocular disease other than POAG or ocular hypertension
* Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
* History of intraocular surgery within the last 3 months
* Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No